Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.

作者: Nicole LoGiudice , Linh Le , Irene Abuan , Yvette Leizorek , Sigrid Roberts

DOI: 10.3390/MEDSCI6010012

关键词: hirsutismNeuroblastomaOrnithineOrnithine decarboxylaseActive ingredientPharmacologyDiseaseMedicineEflornithineColorectal cancer

摘要: The fluorinated ornithine analog α-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of decarboxylase (ODC), the first and rate-limiting enzyme polyamine biosynthesis. ubiquitous essential polyamines have many functions, but are primarily important for rapidly proliferating cells. Thus, ODC potentially a drug target any disease state where rapid growth key process leading to pathology. compound was originally discovered as anticancer drug, its effectiveness disappointing. However, DFMO successfully developed treat African sleeping sickness currently one few clinically used drugs combat this neglected tropical disease. other Food Drug Administration (FDA) approved application active ingredient in hair removal cream Vaniqa. In recent years, renewed interest hyperproliferative diseases has led increased research promising preclinical clinical trials. This review explores use treatment hirsutism, well potential chemopreventive chemotherapeutic agent against colorectal cancer neuroblastoma.

参考文章(114)
Susan LeGendre-McGhee, Photini S. Rice, R. Andrew Wall, Kyle J. Sprute, Ramireddy Bommireddy, Amber M. Luttman, Raymond B. Nagle, Edward R. Abril, Katrina Farrell, Chiu-Hsieh Hsu, Denise J. Roe, Eugene W. Gerner, Natalia A. Ignatenko, Jennifer K. Barton, Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography. Cancer Growth and Metastasis. ,vol. 2015, pp. 63- 80 ,(2015) , 10.4137/CGM.S21216
Frank L. Meyskens, Christine E. McLaren, Daniel Pelot, Sharon Fujikawa-Brooks, Philip M. Carpenter, Ernest Hawk, Gary Kelloff, Michael J. Lawson, Jayashri Kidao, John McCracken, C. Gregory Albers, Dennis J. Ahnen, D. Kim Turgeon, Steven Goldschmid, Peter Lance, Curt H. Hagedorn, Daniel L. Gillen, Eugene W. Gerner, Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial Cancer Prevention Research. ,vol. 1, pp. 32- 38 ,(2008) , 10.1158/1940-6207.CAPR-08-0042
Richard A Hubner, Kenneth R Muir, Jo-Fen Liu, Richard FA Logan, Matthew J Grainge, Richard S Houlston, UKCAP Consortium, Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention Clinical Cancer Research. ,vol. 14, pp. 2303- 2309 ,(2008) , 10.1158/1078-0432.CCR-07-4599
Frank L. Meyskens, Eugene W. Gerner, Scott Emerson, Daniel Pelot, Theodore Durbin, Karen Doyle, Westley Lagerberg, Effect of α-Difluoromethylornithine on Rectal Mucosal Levels of Polyamines in a Randomized, Double-Blinded Trial for Colon Cancer Prevention Journal of the National Cancer Institute. ,vol. 90, pp. 1212- 1218 ,(1998) , 10.1093/JNCI/90.16.1212
Laura D. Gamble, Michael D. Hogarty, Xueyuan Liu, David S. Ziegler, Glenn Marshall, Murray D. Norris, Michelle Haber, Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma Frontiers in Oncology. ,vol. 2, pp. 162- 162 ,(2012) , 10.3389/FONC.2012.00162
David S. Alberts, Janine G. Einspahr, James A. Warneke, Kathylynn Saboda, Rayna Goldman, Yei-Mei Peng, Mikel Aickin, Min Jian Xu, G. Timothy Bowden, Denise J. Roe, Janet A. Foote, Robert T. Dorr, Stuart Salasche, Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine Cancer Epidemiology, Biomarkers & Prevention. ,vol. 9, pp. 1281- 1286 ,(2000)
Howard H. Bailey, KyungMann Kim, Ajit K. Verma, Karen Sielaff, Paul O. Larson, Stephen Snow, Theresa Lenaghan, Jaye L. Viner, Jeff Douglas, Nancy E. Dreckschmidt, Mary Hamielec, Marcy Pomplun, Harry H. Sharata, David Puchalsky, Eric R. Berg, Thomas C. Havighurst, Paul P. Carbone, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer Cancer Prevention Research. ,vol. 3, pp. 35- 47 ,(2010) , 10.1158/1940-6207.CAPR-09-0096
C. Jansen, D. E. Mattox, K. D. Miller, W. E. Brownell, An Animal Model of Hearing Loss From α-Difluoromethylornithine Archives of Otolaryngology-head & Neck Surgery. ,vol. 115, pp. 1234- 1237 ,(1989) , 10.1001/ARCHOTOL.1989.01860340088024
Frank L. Meyskens, Eugene W. Gerner, Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clinical Cancer Research. ,vol. 5, pp. 945- 951 ,(1999)